The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | WM: BTK inhibitors
From the International Myeloma Workshop (IMW) 2019, held in Boston, MA, Jorge Castillo, MD, from Dana-Farber Cancer Institute, Boston, MA, and Ramon Garcia-Sanz, MD, from University Hospital of Salamanca, Salamanca, Spain, discuss the exciting new agents for the treatment of Waldenström’s Macroglobulinemia (WM) that are emerging from current clinical trials. This discussion highlights venetoclax, ibrutinib and newer BTK (Bruton tyrosine kinase) inhibitors such as acalabrutinib and zanubrutinib.
